Extracellular ATP and P2 purinergic signalling in the tumour microenvironment

F Di Virgilio, AC Sarti, S Falzoni, E De Marchi… - Nature Reviews …, 2018 - nature.com
Modulation of the biochemical composition of the tumour microenvironment is a new frontier
of cancer therapy. Several immunosuppressive mechanisms operate in the milieu of most …

Extracellular ATP: a feasible target for cancer therapy

V Vultaggio-Poma, AC Sarti, F Di Virgilio - Cells, 2020 - mdpi.com
Adenosine triphosphate (ATP) is one of the main biochemical components of the tumor
microenvironment (TME), where it can promote tumor progression or tumor suppression …

Gut microbiota, metabolites and host immunity

MG Rooks, WS Garrett - Nature reviews immunology, 2016 - nature.com
The microbiota—the collection of microorganisms that live within and on all mammals—
provides crucial signals for the development and function of the immune system. Increased …

The ectonucleotidases CD 39 and CD 73: novel checkpoint inhibitor targets

B Allard, MS Longhi, SC Robson… - Immunological …, 2017 - Wiley Online Library
Cancers are able to grow by subverting immune suppressive pathways, to prevent the
malignant cells as being recognized as dangerous or foreign. This mechanism prevents the …

Adenosine-A2A receptor pathway in cancer immunotherapy

C Sun, B Wang, S Hao - Frontiers in immunology, 2022 - frontiersin.org
A2A receptors (A2AR), a typical GPCR with a high affinity for adenosine, was expressed in
many immune cells, such as regulatory T cells, cytotoxic T cells, macrophages, etc …

Applying extracellular vesicles based therapeutics in clinical trials–an ISEV position paper

T Lener, M Gimona, L Aigner, V Börger… - Journal of …, 2015 - Taylor & Francis
Extracellular vesicles (EVs), such as exosomes and microvesicles, are released by different
cell types and participate in physiological and pathophysiological processes. EVs mediate …

CD39 and CD73 in immunity and inflammation

L Antonioli, P Pacher, ES Vizi, G Haskó - Trends in molecular medicine, 2013 - cell.com
The enzymatic activities of CD39 and CD73 play strategic roles in calibrating the duration,
magnitude, and chemical nature of purinergic signals delivered to immune cells through the …

Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus

C von Spee-Mayer, E Siegert, D Abdirama… - Annals of the …, 2016 - ard.bmj.com
Objectives Defects in regulatory T cell (Treg) biology have been associated with human
systemic autoimmune diseases, such as systemic lupus erythematosus (SLE). However, the …

Cellular function and molecular structure of ecto-nucleotidases

H Zimmermann, M Zebisch, N Sträter - Purinergic signalling, 2012 - Springer
Ecto-nucleotidases play a pivotal role in purinergic signal transmission. They hydrolyze
extracellular nucleotides and thus can control their availability at purinergic P2 receptors …

Purinergic signalling and immune cells

G Burnstock, JM Boeynaems - Purinergic signalling, 2014 - Springer
This review article provides a historical perspective on the role of purinergic signalling in the
regulation of various subsets of immune cells from early discoveries to current …